HC Wainwright Reaffirms “Buy” Rating for GH Research (NASDAQ:GHRS)

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $40.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 233.61% from the company’s previous close.

GHRS has been the topic of several other research reports. JMP Securities cut their price target on shares of GH Research from $50.00 to $39.00 and set a “market outperform” rating on the stock in a report on Friday, March 1st. Canaccord Genuity Group increased their price objective on shares of GH Research from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday.

GH Research Price Performance

Shares of GHRS opened at $11.99 on Tuesday. The company’s fifty day moving average price is $10.51 and its 200-day moving average price is $8.07. GH Research has a 1-year low of $5.05 and a 1-year high of $14.64. The firm has a market capitalization of $623.84 million, a PE ratio of -19.98 and a beta of 0.80.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). As a group, research analysts anticipate that GH Research will post -0.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. AdvisorShares Investments LLC grew its stake in shares of GH Research by 4.3% during the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after purchasing an additional 1,977 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in GH Research by 16.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 92,784 shares of the company’s stock valued at $932,000 after buying an additional 12,911 shares during the period. PEAK6 Investments LLC increased its holdings in GH Research by 72.9% in the third quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock valued at $405,000 after buying an additional 16,991 shares in the last quarter. Barclays PLC raised its position in shares of GH Research by 98.2% in the third quarter. Barclays PLC now owns 63,590 shares of the company’s stock worth $640,000 after acquiring an additional 31,500 shares during the period. Finally, Lynx1 Capital Management LP boosted its stake in shares of GH Research by 13.8% during the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock worth $11,087,000 after acquiring an additional 133,804 shares in the last quarter. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).